对13例患有帕金森病且有“开-关”波动现象的患者，开展了左旋多巴与苄丝肼新剂型美多芭HBS的开放性研究。

Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.

作者信息

Quinn N P, Marion M H, Marsden C D

机构信息

University Department of Neurology, Institute of Psychiatry, London, UK.

出版信息

Eur Neurol. 1987;27 Suppl 1:105-13. doi: 10.1159/000116204.

DOI:10.1159/000116204

PMID:3322834

Abstract

In a open study in 13 patients with Parkinson's disease with 'on-off' fluctuations, all (n = 3) or part (n = 10) of the usual intake of levodopa (with peripheral decarboxylase inhibitor) was replaced by Madopar HBS for 5-122 days (median 35). Time 'off' increased in 2 of the 3 monotherapy subjects. With combined therapy, time 'on' was increased in 6, unchanged in 2 and reduced in 2. However, 11 of the 13 patients complained of reduced predictability of clinical response with Madopar HBS. Only 4 of the 13 patients preferred to continue with combined standard plus HBS treatment; this continued treatment led to an increase in time 'on' in 3 and a decrease in involuntary movements in 3 patients. Two of these four patients benefited on both counts.

摘要

在一项针对13例患有“开-关”波动的帕金森病患者的开放性研究中，左旋多巴（含外周脱羧酶抑制剂）的全部（n = 3）或部分（n = 10）常规摄入量被美多芭HBS替代5 - 122天（中位数为35天）。3例接受单一疗法的患者中有2例“关”期时间增加。联合治疗时，6例患者“开”期时间增加，2例不变，2例减少。然而，13例患者中有11例抱怨使用美多芭HBS后临床反应的可预测性降低。13例患者中只有4例更愿意继续标准治疗加HBS联合治疗；这种持续治疗使3例患者“开”期时间增加，3例患者的不自主运动减少。这4例患者中有2例在两方面均受益。